Javed Zeeshan, Javed Iqbal Muhammad, Rasheed Amna, Sadia Haleema, Raza Shahid, Irshad Asma, Koch Wojciech, Kukula-Koch Wirginia, Głowniak-Lipa Anna, Cho William C, Sharifi-Rad Javad
Office for Research Innovation and Commercialization, Lahore Garrison University, Lahore, Pakistan.
Department of Biotechnology, Faculty of Sciences, University of Sialkot, Sialkot, Pakistan.
Front Oncol. 2021 Jan 7;10:607607. doi: 10.3389/fonc.2020.607607. eCollection 2020.
Hedgehog (Hh) signaling aberrations trigger differentiation and proliferation in colorectal cancer (CRC). However, the current approaches which inhibit this vital cellular pathway provoke some side effects. Therefore, it is necessary to look for new therapeutic options. MicroRNAs are small molecules that modulate expression of the target genes and can be utilized as a potential therapeutic option for CRC. On the other hand, nanoformulations have been implemented in the treatment of plethora of diseases. Owing to their excessive bioavailability, limited cytotoxicity and high specificity, nanoparticles may be considered as an alternative drug delivery platform for the Hh signaling mediated CRC. This article reviews the Hh signaling and its involvement in CRC with focus on miRNAs, nanoformulations as potential diagnostic/prognostic and therapeutics for CRC.
Onco Targets Ther. 2017-6-30
Adv Exp Med Biol. 2016
Cancer Biother Radiopharm. 2009-12
Front Pharmacol. 2021-1-27
Korean J Gastroenterol. 2017-4-25
Clin Colorectal Cancer. 2016-6
Int J Mol Sci. 2018-9-27
Med Oncol. 2023-1-31
Front Mol Biosci. 2022-9-26
Cancer Cell Int. 2020-10-15
Int J Mol Sci. 2020-9-18
FASEB J. 2020-10
Cancer Cell Int. 2020-7-20
Signal Transduct Target Ther. 2020-2-7
Expert Opin Drug Deliv. 2020-6
Front Cell Dev Biol. 2020-3-10
Cell Stem Cell. 2020-4-2